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Abstract
Cyclic nucleotide phosphodiesterases (PDEs) are important regulators of signal transduction processes mediated by cAMP
and cGMP. One PDE family member, PDE3B, plays an important role in the regulation of a variety of metabolic processes
such as lipolysis and insulin secretion. In this study, the cellular localization and the role of PDE3B in the regulation of
triglyceride, cholesterol and glucose metabolism in hepatocytes were investigated. PDE3B was identified in caveolae,
specific regions in the plasma membrane, and smooth endoplasmic reticulum. In caveolin-1 knock out mice, which lack
caveolae, the amount of PDE3B protein and activity were reduced indicating a role of caveolin-1/caveolae in the
stabilization of enzyme protein. Hepatocytes from PDE3B knock out mice displayed increased glucose, triglyceride and
cholesterol levels, which was associated with increased expression of gluconeogenic and lipogenic genes/enzymes
including, phosphoenolpyruvate carboxykinase, peroxisome proliferator-activated receptor c, sterol regulatory element-
binding protein 1c and hydroxyl-3-methylglutaryl coenzyme A reductase. In conclusion, hepatocyte PDE3B is localized in
caveolae and smooth endoplasmic reticulum and plays important roles in the regulation of glucose, triglyceride and
cholesterol metabolism. Dysregulation of PDE3B could have a role in the development of fatty liver, a condition highly
relevant in the context of type 2 diabetes.
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Introduction
Cyclic nucleotide phosphodiesterases (PDEs) are important
regulators of signal transduction processes mediated by cAMP and
cGMP. The PDE family contains eleven structurally related and
functionally distinct subfamilies (PDE1-11) that differ in their
primary structures, affinities for cAMP and cGMP, responses to
specific effectors and inhibitors, as well as mechanisms through
which they are regulated [1]. PDE3 isoforms are encoded by two
similarly organized genes, PDE3A and PDE3B. These enzymes
hydrolyze cAMP and cGMP with high affinity in a mutually
competitive manner and are inhibited by compounds such as
cilostamide, cilastazol and milrinone [2,3]. The structural
organization of PDE3A and PDE3B proteins is identical with
the catalytic domain found in all PDEs located in the C-terminal
portions of the molecules [2,3]. The catalytic domains of PDE3A
and B are highly conserved, except for an insertion of 44 unique
amino acids that is not found in the catalytic domains of other
PDE families and that also differs in, and thus distinguishes,
PDE3A and B isoforms [2,3]. Their N-terminal regulatory
domains are quite divergent, consisting of two hydrophobic
regions important for membrane association of these enzymes.
Full-length PDE3s (Mw 135 kDA) are found in association with
membranes; smaller PDE3A forms are found in cytosolic fractions
[4]. Furthermore, PDE3B has been shown to be localized to the
endoplasmic reticulum (ER) and to specific detergent-resistent
parts of the plasma membrane, caveolae [5,6]. Caveolae are
special forms of lipid rafts observed as small flask-shaped 50–
100 nM invaginations of the plasma membranes and are
particularly abundant in adipocytes. They have a high content
of sphingolipids, cholesterol and are stabilized by one or more
isoforms of caveolin. Caveolae are believed to be important in the
organization of signal transduction events, particularly insulin and
cAMP signalling [7]. The exact intracellular location of the
hepatocyte PDE3B has not been elucidated. The N-terminal
region of PDE3B contains regulatory phosphorylation sites [2,3].
Multisite phosphorylation of PDE3s has, for example, been
demonstrated in adipocytes, hepatocytes and HeLa cells [8,9]
which is believed to be important in the regulation of PDE3
activity and in interaction with other proteins [2,3].
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sion. PDE3A is highly expressed primarily in the cardiovascular
system, for example in platelets, smooth muscle cells and cardiac
myocytes [2,3]. PDE3B on the other hand is relatively highly
expressed in cells important in energy metabolism, such as white
and brown adipocytes, pancreatic b-cells and liver [2,3] indicating
a role for this enzyme in the regulation of metabolism.
Recent results from PDE3B transgenic mouse models do indicate
that PDE3B plays an important role in overall regulation of energy
metabolism [10,11]. For example, mice that specifically overexpress
PDE3B in pancreatic b-cells demonstrate glucose intolerance and
impaired insulin response to glucose and glucagon-like peptide-1
(GLP-1) [10]. The phenotype of PDE3B knock out (KO) mice is
complex. Hence, on one hand PDE3B KO mice are lean and have
improved insulin secretion but they also exhibit glucose intolerance,
insulin resistance and increased lipolysis [11]. The role of
hepatocyte PDE3B in the regulation of lipid and glucose
metabolism remains unknown. However, clamp studies in PDE3B
KO mice show increased glucose production and reduced ability of
insulin to suppress glucose production indicating multiple roles for
this enzyme in hepatocytes [11].
In this study we demonstrate that, in hepatocytes, PDE3B is
localized to caveolae and smooth ER and that the enzyme has an
important role in the regulation of triglyceride, cholesterol and
glucose metabolism in these cells.
Materials and Methods
Ethics statement
All animals were handled in strict accordance with good animal
practice as defined by the national and local animal welfare
bodies, and all animal work was approved by the Ethics
Committee at Lund University, Lund, Sweden.
Materials
C57BL/6 male mice were purchased from Taconic (Skensved,
Denmark). Caveolin-1 KO mice on the C57BL/6 background,
obtained from the Jackson Laboratory (Bar Harbor, Maine, USA),
werefurtherbackcrossed onthe samebackground andgenotyped as
described by Razani et al [12]. PDE3B deficient mice were
generated and characterized as previously described in [11] (a
fragmentcontainingexon1ofthemousePde3bgenewasclonedinto
the pBluescript and used to construct the targeting vector).
Antibodies against caveolin-1 (rabbit polyclonal) and adenylyl
cyclase (AC) V were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA); flotillin-1, Na
+K
+-ATPase, nucleoporin
p62 and BiP from BD Transduction Laboratories. Antibodies
against phosphoenolpyruvate carboxylase [PEPCK (PCK1)] were
obtained from Abgent (San Diego, CA, USA). Anti-PDE3B
antibodies used for immunoblot analysis were raised in rabbits
against the peptideCGYYGSGKMFRRPSLP and affinity purified.
For electron microscopy affinity purified antibodies against the C-
terminal (CT) part of PDE3B were generated in rabbit using the
peptide NASLPQADEIQVIEEA. As secondary antibody, HRP-
goat anti-rabbit antibody (BioSource, Invitrogen, Carlsbad, CA,
USA)was used.If not otherwise stated,reagents and chemicalswere
obtained from Sigma-Aldrich (Stockholm, Sweden).
Subcellular fractionation
Hepatocyte subcellular fractions were prepared according to
Fleisher and Kervina [13] with a few modifications based on a
study by Tuma et al [14]. Isolated and washed hepatocytes (35–
100610
6 cells) from C57BL/6 mice or washed whole livers from
10–12 weeks old caveolin-1 KO and wild type (WT) mice were
homogenized with a Dounce homogenizer (10–15 strokes) in
10 ml buffer A (10 mM HEPES pH 7.5, 0.25 M sucrose, 1 mM
EDTA, 1 mM NaF, 0.2 mM sodium orthovanadate, 1 mg/ml
pepstatin A, 10 mg/ml leupeptin and 10 mg/ml antipain). The
homogenate was centrifuged (2806g, 5 min). The supernatant was
saved and the pellet rehomogenized in 2.5 ml buffer A and
centrifuged as above (2806g, 5 min). The first and second
supernatants were combined and further centrifuged (1 5006g
for 10 min). The resulting supernatant (sup 1) was further
centrifuged as described below and the pellet was homogenized
in 2 ml buffer B (10 mM Tris pH 7.4, 0.25 M sucrose, 0.5 mM
MgCl2, 3 mM NaF, 0.6 mM sodium orthovanadate, 3 mg/ml
pepstatin A, 30 mg/ml leupeptin and 30 mg/ml antipain). The
homogenate was supplemented with 6.75 ml of a sucrose rich
buffer (2 M sucrose, 10 mM Tris (pH 7–8) and 0.5 mM MgCl2 in
order to yield a final concentration of 1.6 M sucrose. The
suspension was transferred into a rotor tube, overlayed with 2 ml
buffer B and centrifuged (SW41, 70 9006g, 70 min). The
interphase with plasma membranes was collected and the pellet
containing nuclei was rehomogenized in buffer A supplemented
with sucrose to a final concentration of 2 M, and centrifuged
(70 9006g, 60 min). The pellet, referred to as the nuclei fraction,
was suspended in 1 ml buffer C (50 mM TES pH 7.4, 50 mM
sucrose, 1 mM EDTA, 0.1 mM EGTA, 1 mg/ml pepstatin A,
10 mg/ml leupeptin and 10 mg/ml antipain). The interphase
containing plasma membranes was resuspended in 6 ml buffer A
and centrifuged (1 7006g, 10 min). The pellet was used for
caveolae enrichment as described in the next section, or further
purified with regard to the plasma membrane on a 1.45 M sucrose
gradient according to Fleisher and Kervina [13]. The purified
plasma membrane fraction was finally suspended in 1 ml buffer C.
The supernatant from the first centrifugation step (sup1) was
centrifuged twice (8 0006g, 15 min) to isolate mitochondria. The
combined pellets were resuspended in buffer A and centrifuged
(25 0006g, 10 min), the lower brown part of the pellet was
resuspended in 1 ml buffer C and is referred to as the
mitochondria fraction. The supernatant from the 8 0006g
centrifugation was further centrifuged (124 0006g, 60 min) and
the pellet referred to as internal membranes were suspended in
1 ml buffer C. Each step was performed at 4uC.
Caveolae enrichment
Plasma membranes (originating from 50–115610
6 isolated
hepatocytes) prepared as described above were resuspended in
1 ml 0.5 M Na2CO3 pH 11 with 1 mg/ml pepstatin A, 10 mg/ml
leupeptin and 10 mg/ml antipain and sonicated with a probe-type
sonifier (soniprep 150) 3620 sec according to previously well
described procedures [15–17]. The sonicated plasma membranes
were thereafter placed in the bottom of a tube and mixed with 1 ml
90% sucrose in 25 mM MES and 0.15 M NaCl to yield a final
concentration of 250 mMNa2CO3 and 45% sucrose.On top of this
solution, 4 ml 35% sucrose in 25 mM MES, 0.15 M NaCl and
250 mM Na2CO3 pH 11 was added. Finally, 4 ml of 5% sucrose in
25 mM MES, 0.15 M NaCl and 250 mM Na2CO3 pH 11 was
layered on top. The gradient was centrifuged using a SW41
Beckman rotor at 39 0006g for 18–19 hrs at 4uC. From the top of
the tube, 1 ml fractions were collected. Before measuring PDE3
activity, pH was neutralized (pH 7–8) using approximately 30 mlo f
5.0 M HCl per ml sample. Each step was performed at 4uC.
Preparation of detergent resistant membranes and
Superose-6 chromatography
Isolated mouse hepatocytes (20–100610
6) were homogenized in
1 ml buffer A and centrifuged (2806g, 10 min). The supernatant
PDE3B in Hepatocytes
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containing total membranes. The pellet was homogenized in
1.5 ml of detergent containing buffer, buffer D (25 mM HEPES
pH 7.4, 150 mM NaCl, 1 mM EDTA, 10 mM Na4O7P2, 1% NP-
40, 5 mM NaF, 1 mM PMSF, 1 mM Na3VO4,1mg/ml pepstatin
A, 5 mg/ml leupeptin and 5 mg/ml antipain). Half of the
homogenized pellet was immediately subjected to centrifugation
(10 0006g for 10 min, 4uC). The supernatant was filtered (0.2 mm
pore size) and thereafter subjected to gel filtration chromatography
on a Superose-6 (10/300) column with a separation range of 5–
4 000 kDa (Amersham Pharmacia Biotech AB, Uppsala, Sweden)
in a fast protein liquid chromatography system. The remaining
part of the homogenized pellet from the 175 0006g centrifugation
was incubated for 1 h at 4uC and then re-centrifuged (175 0006g
for 50 min, 4uC). The subsequent supernatant contained solubi-
lized membranes and the pellet detergent resistant membranes
(DRM). The pellet was homogenized in 0.75 ml buffer D and
thereafter subjected to centrifugation (10 0006g for 10 min, 4uC).
The supernatants containing either solubilized membranes or
DRM were filtered (0.2 mm pore size) and thereafter subjected to
gel filtration chromatography on a Superose-6 (10/300) column.
The column was equilibrated and eluted with buffer D and the
flow rate was set to 0.5 ml/min and 0.4 ml fractions were
collected. Absorbance at 280 nm was monitored on-line and gel
filtration standards (Bio-Rad, Hercules, CA, USA) ranging from
1–670 kDa was used.
Immuno-electron microscopy
Livers from C57BL/6 mice were perfused in situ with 50 ml
37uC phosphate buffered saline (PBS) followed by 100 ml 1.5%
paraformaldehyde, 0.5% glutaraldehyde in 0.1 M phosphate
buffer, pH 7.2. Liver pieces were dissected and left in fixative
for 1 h. The tissue pieces were washed in 0.1 M phosphate buffer
pH 7.2, dehydrated in graded ethanol concentrations to 100%
ethanol and embedded in Lowicryl HM120 (TAAB, Reading,
UK) as previously described [18,19]. Ultrathin sections were cut
and placed on gold grids. Sections were blocked with PBS (pH 7.2)
containing 0.5% bovine serum albumin (BSA) and incubated over
night at 4uC with primary antiserum (PDE3B-CT diluted 1:50 in
PBS containing 0.25% BSA and 0.25% Triton X-100) or PBS
containing 0.25% BSA and 0.25% Triton X-100 (as negative
control). The sections were washed thoroughly in PBS and
thereafter incubated for 1 h with gold-conjugated (10 nm
diameter gold particles) goat-anti-rabbit IgG (diluted 1:20,
Amersham Pharmacia Biotech AB, Uppsala, Sweden) and washed
again in PBS. All sections were contrasted with 0.5% lead citrate
and 4% uranyl acetate before examination in a Philips CM10
transmission electron microscope.
PDE-assay
PDE activity was measured in duplicate in the presence or
absence of 3 mM of the specific PDE3 inhibitor OPC3911 [20]
(Otsuka Pharmaceuticals Co., Tokyo, Japan), as described
previously [10]. The assay was performed at 30uC in a total
volume of 300 ml containing 50 mM TES pH 7.4, 250 mM
sucrose, 1 mM EDTA, 0.1 mM EGTA, 8.3 mM MgCl2, 0.5 mM
cAMP, 1 mCi/ml
3H-cAMP and 0.6 mg/ml ovalbumin.
Immunoblot analysis
Different hepatocyte fractions were mixed with Laemmli sample
buffer and subjected to SDS-polyacrylamide gel electrophoresis
(PAGE) (9–12% acrylamide) before electrotransfer of the proteins
to hybond-C extra (Amersham Bioscienses, Buckinghamshire,
UK) (fractions from subcellular fractionation) or PVDF mem-
branes. Membranes were blocked for 1 h with 5–8% fat free milk
in 20 mM Tris pH 7.6, 137 mM NaCl, and 0.1% Tween-20
before incubation with antibodies as indicated at 4uC over night.
The analyses were performed using Super Signal reagents (Pierce,
Rockford, USA) and CCD camera (LAS 1 000 Plus, Fuji, Tokyo,
Japan) or exposure to Kodak autoradiographic film.
Preparation of primary hepatocytes
PDE3B KO and WT mice (3–5 months old) were anesthetized
with an intraperitoneal injection of midazolam (Dormicum,
Hoffman- La Roche, Basel, Switzerland) and a mixture of
fluanison/fentanyl (Hypnorm, Janssen, Beerse, Belgium). The
livers were subjected to non-recirculating two-step collagenase
perfusion. The perfusion was done through the portal vein
according to a protocol modified from Carlsson et al [21]. In the
first step, Hank’s Balanced Salt Solution (HBSS) without calcium
and magnesium (Invitrogen Corporation, Carlsbad, CA, USA)
supplemented with 2 mM EGTA, 20 mM HEPES and 10 mM
NaHCO3, pH 7.4, was infused with a pump for 6 minutes with a
flow rate of 12–15 ml/min. In the second step, the liver was
perfused with William’s E medium with Glutamax (Invitrogen
Corporation, Carlsbad, CA, USA) supplemented with 50 U/ml,
penicillin, 50 mg/ml streptomycin, 0.28 mM sodium ascorbate,
0.1 mMN a 2SeO3 and 0.45 mg/ml collagenase type IV (Sigma) for
6 min at the same flow rate as above. The perfusion solutions were
kept in a 37uC water bath and continuously infused with 95% O2
and 5% CO2. After the perfusion, the livers were excised and the
hepatocytes were flushed out from the liver with ice cold William’s
E medium supplemented as described (without collagenase) and
filtered through a 250 mm pore size mesh nylon filter (Sintab
Produkt AB, Oxie, Sweden) followed by a 100 mm pore size nylon
filter (Falcon, BD Bioscience, Stockholm, Sweden). The cells were
washed with William’s E medium supplemented as previously
described but with the addition of 3 nM insulin (Actrapid, Novo
Nordisk, Denmark) and 1 nM dexamethasone. The cells were
centrifuged at 506g for 2 minutes between the washes. The
viability of the cells was more than 70% as determined by trypan
blue exclusion. Hepatocytes used for triglyceride and RNA
extraction were collected at this step and not cultured. For other
experiments, hepatocytes were seeded at a density of 10610
6
cells/10 cm or 2610
6 cells/well in 6-well Primaria
TM plates (BD
Bioscience, Stockholm, Sweden). The cells were allowed to attach
for 4–5 hours, thereafter the medium and the non-attached cells
were aspirated and fresh medium added for culture over night.
Activation of PDE3B in primary hepatocytes
Hepatocytes were cultured overnight on 10 cm Primaria
TM
dishes and thereafter washed twice with PBS. The cells were
treated without or with 10 nM insulin or 10 nM glucagon for
15 minutes in 5 ml DMEM medium without glucose (Invitrogen
Corporation, Carlsbad, CA, USA) supplemented with 5 mM
glucose, washed in PBS and thereafter scraped and homogenized
in homogenization buffer (50 mM TES, 250 mM sucrose, 1 mM
EDTA, 0.1 mM EGTA, 1 mg/ml pepstatin A, 10 mg/ml leupep-
tin and 10 mg/ml antipain, pH 7.4) with a glass/teflon homog-
enizer. The homogenate was centrifuged (2806g, 10 min) and the
supernatant was analyzed for PDE3 activity as previously
described. The PDE3 activity was normalized to protein content
using Bradford protein assay.
RNA isolation and quantitative real-time RT-PCR
Non-cultured hepatocytes (10610
6cells/ml) (nine month old
mice) were homogenized in lysis buffer (RLT buffer, Qiagen, Solna,
Sweden) using syringe and needle. The homogenate was either
PDE3B in Hepatocytes
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using RNeasy kit (Qiagen, Solna, Sweden). Primers were designed
on the basis of the sequences available at the NCBI gene bank and
produced by DNA technologies (Aarhus, Denmark). Primer
sequences and accession numbers are presented in Table 1. The
real-time RT-PCR analyses were performed on a Miniopticon
Thermal Cycler (BioRad, Hercules, CA, USA) and the software MJ
Opticon Monitor (BioRad) was used for analysis. SYBR Green I
was used as the source of fluorescence and cyclophilin A (CypA) was
used as reference gene. The concentration of primers was 400 nM
and 250 ng of template was used under the following conditions:
25uC for 5 min, 50uC for 10 min, 95uC for 5 min and then 55
cycles of 94uC for 10 sec, 53uC for 10 sec and 72uC for 1 min. The
specificities of the PCR products were confirmed by single
dissociation curves. The mRNA expression was calculated using
the 2
2DDC(t)-formula and expressed as arbitrary units in relation to
cyclophilinA mRNA expression.
Glucose production
Hepatocytes were cultured overnight in 6-well plates, washed
twice with PBS, and thereafter incubated in Krebs-Ringer
bicarbonate buffer (120 mM NaCl, 5 mM NaHCO3, 5 mM KCl,
1.2 mM KH2PO4, 2.5 mM CaCl2, 1.2 mM MgSO4, 0.2% BSA,
10 mM HEPES, pH 7.2–7.4) supplemented with 5 mM Na-
pyruvate and 5 mM Na-lactate as gluconeogenic substrate. The
cells were incubated for 4 h after which the culture medium was
collected and centrifuged and glucose concentration was deter-
mined with a reagent based on glucose oxidase/hydrogen
peroxidase enzymatic reaction (DiaSys Diagnostic Systems, Holz-
heim, Germany). The glucose concentration was normalized to cell
density determined as protein content using Bradford protein assay.
Hepatocyte triglyceride content
Non-cultured hepatocytes (about 2610
6 cells) were homogenized
in 200 ml William’s E medium supplemented with Complete
protease inhibitor cocktail (Roche, Bromma, Sweden), 5 mM NaF
and 1% Triton X-100. The homogenate (25 or 50 ml) was
transferred to a glass tube containing 3 ml chloroform/methanol
(2:1) solution and stored in a N2 environment at 4uC overnight.
Water(1.5 ml)wasadded and the tubes werecentrifuged at 20006g
for 10 min. After removal of the upper layer the wash step was
repeated once. The samples were dried under N2 and resuspended
in chloroform. Aliquots were transferred into Eppendorf tubes and
air-dried. Thesit (Bio Chemika, Sigma-Aldrich, Stockholm, Swe-
den; 20%, v/w, in chloroform) was added and thereafter the sample
was solubilized in water and incubated at 37uC for 10 min. A
standard curve was prepared with use of different concentrations of
triolein treated in parallel with the samples. Triglyceride reagent
(Infinity
TM, Thermo Electron, Melbourne, Australia) was added
according to the manufacturer and absorbance was measured at
510 nm.Thetriglyceridecontentwasnormalized toproteincontent
using Bradford protein assay.
Cholesterol and protein measurement
Livers previously fixed in formaldehyde (150 mg of dried tissue/
sample) were chopped with a scalpel into cubes of around 1 mm
3.
Lipids were extracted with methanol:chloroform (2:1) as described
in the section ‘‘Hepatocyte triglyceride content’’. Cholesterol levels
were determined by measuring the amount of H2O2 produced by
cholesterol oxidase using Infinity
TM Cholesterol Liquid Stable
Reagent (Thermo Electron, Melbourne, Australia). This assay was
optimized for measuring cholesterol in tissue samples. Protein was
measured using a bicinchoninic acid (BCA) protein reagent kit
from Pierce (Rockford, USA).
Statistics
Data are presented as mean6standard error of the mean (SEM)
from the indicated number of experiments. Data was analyzed
using a two-tailed paired student’s t-test (hepatocyte stimulation
and glucose output) or a two-tailed non-parametric Mann-
Whitney test (triglyceride and cholesterol content and mRNA
expression). Differences with a p,0.05 were considered signifi-
cant. *p,0.05, **,0.01 and ***,0.001.
Results
Hepatocyte PDE3B is distributed in plasma membrane
and internal membrane fractions
To examine the intracellular localization of PDE3B in mouse
hepatocytes, we performed subcellular fractionation of isolated mouse
hepatocytes, as described in Materials and Methods. Subcellular
fractions were first analyzed with regard to subcellular markers;
Na
+K
+ -ATPase for plasma membrane, BiP (an ER chaperone) for
ER and Nucleoporin p62 (nucl) for the nucleus (Figure 1b). As seen in
Figures 1a and 1b, PDE3B was found in the plasma membranes and
internal membranes, the latter consisting, to a large extent, of ER.
According to Figure 1a, the proportion of PDE3B in the plasma
membrane and internal membrane fraction is 1:5. When PDE3B
activity in subcellular fractions was expressed per mg protein the
following results were obtained for plasma membranes, internal
membranes, mitochondria and nucleus, respectively; 5.561.7,
10.263.2, 4.461.2 and 2.960.83 pmol PDE3B/mg protein (n=3,
mean6SEM). The subcellular fractions were also analyzed for the
caveolae marker caveolin-1 and the lipid-raft marker flotillin-1. Both
these proteins were present selectively in the plasma membrane
(Figure1b).PDE4, anothermajor hepatocyte PDE,wasmainlyfound
in the cytosolic fraction (data not shown).
Plasma membrane PDE3B is associated with caveolae in
hepatocytes
In order to investigate the possibility that PDE3B is localized to
caveolae in hepatocytes, we isolated caveolae from the plasma
membrane of isolated mouse hepatocytes. The plasma membranes
were sonicated in high concentration of Na2CO3 and put on a
Table 1. Primer sequences used for quantitative real-time RT-PCR.
Gene Primer fwd Primer rev Accession nr
Phosphoenolpyruvate carboxy kinase (PEPCK) tatctggaggaccaggtcaa tagatctcagcgcatgctgt NM_011044
Peroxisome proliferator activated receptor gamma (PPARc) gaactgcagctcaagctgaa tgaaggctcatgtctgtctc NM_011146
Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) gcagtcagtgggaactattgca cggcttcacaaaccacagtct NM_008255
Sterol regulatory element binding transcription factor 1 (SREBF-1) ggagccatggattgcacatt ggaagtcactgtcttggttgttga NM_011480
doi:10.1371/journal.pone.0004671.t001
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components of the plasma membrane fraction. After sucrose
gradient fractionation of the sonicated plasma membrane a milky
band was detected at the interface of 5 and 35% sucrose. All of the
PDE3B activity appeared together with flotillin-1, caveolin-1 and
cholesterol in the caveolae/raft enriched fraction (Figures 2a and
2c). This fraction (fraction 6) contained 33% of total proteins
whereas factions 7–8 contained 20% and fractions 9–13 contained
42% of total proteins (Figure 2b). When caveolae were enriched
from detergent resistant plasma membrane of hepatocytes the
same results were obtained (data not shown).
The importance of caveolin-1 for PDE3B expression was
studied using caveolin-1 KO mice. The lack of caveolin-1 results in
the absence of caveolae [12]. Thus, we isolated plasma
membranes from livers from caveolin-1 KO mice and measured
the level of PDE3B protein and activity. As seen in Figure 3, PDE3
protein and activity were significantly lower in plasma membranes
from the caveolin-1 KO mice compared to WT mice. In total
homogenates from caveolin-1 KO mice PDE3 activity was slightly
lower (3.8860.22) compared to WT mice (4.4060.65) (n=3, not
significant). These results show that caveolin-1 and caveolae are
important for determining the amount of PDE3B protein in the
plasma membrane of hepatocytes.
To further study the possible association of PDE3B with
caveolae, we took advantage of the fact that caveolae are detergent
resistant. Total membranes, solubilized membranes and detergent
resistant membranes (DRM) were prepared from mouse hepato-
cytes. The solubilized membranes and DRM fractions were
subjected to superose-6 gel filtration chromatography. PDE3
activity in the total membrane fraction (detergent-treated,
10 0006g supernatant) eluted in two peaks, one with a Mw
slightly above 670 kDa (elution volume 10–12 ml) and one
corresponding to the void volume (.4 000 kDa, elution volume
7–8 ml) (Figure 4). PDE3 from the solubilized membranes
(detergent-treated, 100 0006g supernatant) eluted with the ‘‘10–
12 ml peak’’ whereas PDE3 in the DRM (detergent-treated,
100 0006g pellet) eluted primarily with the void volume which
may represent PDE3 associated with caveolae and/or lipid rafts.
Figure 1. Localization of PDE3B in isolated hepatocytes.
Hepatocytes (35–100610
6) were isolated from C57BL/6 mice and
subjected to subcellular fractionation. Four compartments were
isolated; the plasma membranes (PM), internal membranes (IM),
mitochondria (Mit) and Nuclei (Nucl). The fractions were subjected to
PDE3 activity measurements (a) and immunoblot analysis (b) with
antibodies against PDE3B, caveolin-1 (Cav-1, a caveolae marker),
flotillin-1 (Flot-1, a lipid raft marker), Na
+K
+-ATPase (NaKA, a PM
marker), BiP (ER marker) and nucleoporin p62 (Nucl, a nucleus marker).
PDE3 activities are shown as mean6SEM and immunoblots as one
representative experiment (n=4). Amount of proteins loaded on the
gel: PM, 79 mg; IM, 82 mg; Mitochondria, 31 mg; Nuclei, 31 mg.
doi:10.1371/journal.pone.0004671.g001
Figure 2. PDE3B is present in caveolae-enriched fractions of
hepatocyte plasma membranes. Plasma membranes isolated from
mouse hepatocytes (50–120610
6) were sonicated in NaCO3 and
subjected to sucrose gradient fractionation as described in Materials
and Methods. Fractions of 0.8 ml were collected starting from the top.
The fractions were analyzed for PDE3 activity and cholesterol (a),
proteins (b) and subjected to immunoblot analysis (90 ml of each
fraction) using antibodies against PDE3B, caveolin-1 (Cav-1) and flotillin-
1 (Flot-1) (c). One representative experiment is shown (n=4).
doi:10.1371/journal.pone.0004671.g002
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relation to the ‘‘10–12 ml peak’’ was estimated to be 1:2.
PDE3B is associated with smooth endoplasmic reticulum
In order to study PDE3B localization in internal membranes at
the ultrastructural level, transmission electron microscopy (TEM)
with immunogold labeling for PDE3B was employed. Thorough
examination of several liver sections from different mouse livers
revealed that the majority of the labeling for PDE3B was localized
to smooth ER (Figure 5). In addition, weak PDE3B labeling was
detected in rough ER as well as in mitochondria (Figure 5). Plasma
membranes displayed weak labeling only (data not shown).
Control sections displayed randomly scattered labeling only.
Smooth ER has previously been shown to be in close association
with glycogen particles [22–24]. As seen in Figure 5, PDE3B is
located in close proximity to the glycogen particles which appear
as pale areas among the smooth ER.
Basal glucose production is elevated in PDE3B KO mice
Hepatocytes isolated from C57BL/6 mice were cultured over
night and thereafter stimulated without or with insulin or glucagon
for 15 minutes. Cell homogenates were analyzed for PDE3
activity. As seen in Figure 6a, stimulation of hepatocytes with
either insulin or glucagon induced activation of PDE3 by 35 and
45%, respectively, in agreement with previous results from rat
hepatocytes [25–26]. Activation of PDE3B by insulin and
glucagon has previously been suggested to play a role in
hormone-mediated regulation of rat hepatocyte glucose produc-
tion [27]. Indeed, as shown in Figure 6b, PDE3B KO mouse
hepatocytes showed increased glucose production as compared to
WT hepatocytes which is in agreement with previously performed
clamp studies in these mice [11]. Furthermore, PDE3B KO
hepatocytes showed increased mRNA (Figure 6c) and protein
levels (Figure 6d) of the key gluconeogenic enzyme phosphoenol-
pyruvate carboxykinase (PEPCK).
Triglyceride- and cholesterol contents are increased in
hepatocytes isolated from PDE3B KO mice
Triglycerides (Figure 7a) and cholesterol (Figure 7b) were
analyzed in isolated hepatocytes. Both triglycerides and cholesterol
were increased in PDE3B KO hepatocytes. The increments were
associated with elevated levels of peroxisome proliferator-activated
receptor c (PPARc) and sterol regulatory element-binding protein
1c (SREBP1c) mRNAs, both key lipogenic transcriptional factors
(Figures 7c and 7d), as well as mRNA for hydroxyl-3-methylglu-
taryl coenzyme A (HMG CoA) reductase, a rate limiting enzyme
in cholesterol synthesis (Figure 7e).
Discussion
In this study we demonstrate that PDE3B is localized to
caveolae/lipid raft regions in the plasma membrane as well as in
smooth ER. Further, we show that PDE3B plays important roles
in the regulation of glucose, triglyceride and cholesterol metab-
olism in hepatocytes.
The localization of PDE3B to caveolae is highly interesting,
since caveolae have been suggested to be important in the
organization of cellular signalling as well as in lipid synthesis and
cholesterol homeostasis [7]. The presence of caveolae in
hepatocytes has previously been demonstrated using different
approaches. Plasma membranes of isolated rat hepatocytes has
been shown to contain sphingolipid-enriched microdomains with
high amounts of cholesterol and caveolin-1 [28], and the presence
of caveolae in the hepatocyte plasma membrane has been shown
directly using rapid-freeze, deep-etching electron microscopy [29].
In agreement with the presence of caveolae in hepatocyte plasma
membranes, in this study we detect caveolin-1 and flotillin-1,
markers for caveolae and lipid rafts, respectively, specifically in the
plasma membrane of isolated mouse hepatocytes and fractionation
of sonicated plasma membranes in a sucrose gradient resulted in
co-migration of caveolin-1, flotillin-1 and cholesterol. Further-
more, results from caveolin-1 KO mice suggest an important role
of caveolin-1 in hepatocyte lipid droplet formation and liver
regeneration [30–32]. The finding that caveolin-1 KO livers show
reduced levels of both PDE3B activity and protein expression
indicates a role of caveolin-1/caveolae in the stabilization of the
PDE3B protein which has also been demonstrated for the
adipocyte PDE3B [5]. Our results demonstrating that PDE3B in
hepatocytes is localized to distinct cellular locations, plasma
membrane/caveolae as well as smooth ER, is in agreement with
recent results in adipocytes [5,6]. Exactly which is the role for
PDE3B at these cellular locations needs to be further investigated.
In this study, we demonstrate increased glucose production and
increased level of PEPCK mRNA and protein in hepatocytes from
PDE3B KO mice, which is in agreement with previous studies in
Figure 3. PDE3B protein is reduced in plasma membranes
isolated from livers of caveolin-1 KO mice. Plasma membranes
isolated from WT and caveolin-1 KO livers were analyzed for PDE3
activity (a) and subjected to immunoblot analysis with antibodies
against PDE3B, flotillin-1 (flot-1) and caveolin-1 (cav-1) (b). PDE3
activities (mean6SEM) were significantly different in the two groups
(p,0.046). One immunoblot (34 mg protein/lane) with two represen-
tative experiments are shown (n=5).
doi:10.1371/journal.pone.0004671.g003
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100610
6) and treated with detergent. A portion was used to isolate non-solubilized detergent resistant membranes (DRM) and solubilized
membranes. The different membranes were subjected to Superose-6 chromatography. Fractions were collected and analyzed for PDE3 activity. One
representative experiment is shown (n=4).
doi:10.1371/journal.pone.0004671.g004
Figure 5. Transmission electron micrographs of mouse hepatocytes; PDE3B is localized to the smooth ER. Sections of lowicryl
embedded mouse livers with immunogold labeling for PDE3B (A and C). B and D: negative control with omission of the primary antibody. C and D are
higher magnifications of the indicated areas in A and B, respectively. Arrows show examples of gold labeling. Representative micrographs are shown
(n=4). G; Glycogen storage M; Mitochondria, Nucl; nucleus, rER; rough endoplasmic reticulum, sER; smooth ER.
doi:10.1371/journal.pone.0004671.g005
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liver) and with studies using PDE3 inhibitors [11,27]. The increase
in glucose production observed in isolated hepatocytes is not
extensive and whether this increase can fully explain the increased
production of glucose seen in vivo in PDE3B KO mice is difficult to
know. Although we culture the hepatocytes on Primaria
TM dishes
to keep as much as possible of the original properties of the cells
[33], the hepatocytes most likely have reduced biological
responsiveness compared to the in vivo situation in PDE3B KO
mice. Furthermore, a number of defects related to the storage of
triglycerides and cholesterol were identified in hepatocytes from
PDE3B KO mice. Thus, we found up-regulation of triglyceride
levels in hepatocytes as was the case in PDE3B KO livers [11] and
of SREBP1c, one of two transcriptional factors encoded by
SREBF1 [34]. The expression of SREBP1c predominates in the
liver and has previously been shown to be regulated by insulin and
increased intracellular cAMP [34]. In this study we demonstrate a
specific role of PDE3B in cAMP mediated regulation of SREBP1c.
Nuclear SREBPs is known to interact with cAMP response
element binding protein (CREBP)-binding protein (CBP) and
PPARc–regulated coactivator-1b (PGC-1b) which leads to
upregulation of fatty acid synthase and suppression of PEPCK
gene expression in liver in response to insulin [34]. Cyclic AMP
has also been shown to contribute to the regulation of HMG CoA
reductase [35], however, little is known regarding involvement of
specific PDEs, such as PDE3B, in this process and in the
regulation of cholesterol homeostasis. In this study we show that
indeed PDE3B seems to be important in this context but the exact
signalling pathways in the regulation of HMG CoA reductase and
cholesterol synthesis needs to be further evaluated. Thus, in
hepatocytes from PDE3B KO mice, increased triglyceride and
cholesterol biosynthesis occurred in parallel with elevated
gluconeogenesis. At this point we can not completely exclude that
decreased breakdown and/or release of triglycerides and choles-
terol contribute to the increased levels of the lipids in the PDE3B
KO hepatocytes. However, the increased expression of PPARc,
SREBP1c and HMG CoA reductase together with previous results
[11] showing increased expression of fatty acid synthase (FAS) in
PDE3B KO liver, indicate that increased biosynthesis contribute
to the fatty liver phenotype. Indeed increased accumulation of fat
in the liver is highly relevant in the context of type 2 diabetes
(T2D) and the metabolic syndrome [36,37]. It has been estimated
that 70–80% of T2D patients have non alcoholic fatty liver
disease. This disease covers a spectrum of liver diseases from
steatosis to nonalcoholic steatohepatitis and cirrhosis. Indeed,
increased fat accumulation in the liver appears to be a marker of
hepatic insulin resistance and a close correlate of all components of
the metabolic syndrome independent of obesity. The role of
defect/dysregulated PDE3B in fatty liver development needs to be
further investigated.
In summary, we demonstrate that, in mouse hepatocytes,
PDE3B is localized in caveolae/raft regions in the plasma
Figure 6. Hormonal regulation and glucose production in mouse hepatocytes. Hepatocytes were isolated from C57BL/6 mice and cultured
on Primaria plates. After 18 hours the hepatocytes were incubated for 10 min with 10 nM insulin, 10 nM glucagon or without stimuli (Ctrl). PDE3
activity was measured in total homogenates (a). Values represent mean6SEM (p,0.032 for Insulin, p,0.024 for Glucagon, n=5). Hepatocytes were
isolated from PDE3B KO and WT mice. For glucose production (b) and Western blot analysis of PEPCK (d), the hepatocytes were cultured on Primaria
plates over night before the experiment. RNA for PEPCK mRNA expression analysis (c) was isolated from non-cultured hepatocytes. Values are
means6SEM. Glucose production: p,0.006, n=7. PEPCK mRNA: p,0.02, analyzed in duplicate in two independent experiments from two mice of
each genotype. PEPCK western blot: one representative experiment is shown, n=4.
doi:10.1371/journal.pone.0004671.g006
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important role in the regulation of triglyceride, cholesterol and
glucose metabolism in these cells.
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